Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients

This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.

Source: CancerNetwork - January 21, 2017 Category: Cancer & Oncology Authors: Richard S. Finn, MD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news